Vance Street Capital acquires Injectech, expands medical molding platform

Vance Street Capital has acquired Injectech from The West Group, marking the latest addition to the private equity firm’s expanding VSC Medical Molding platform.

The deal broadens the platform’s single-use fluid management offerings for medical device, life science and bioprocessing customers. Injectech joins Plastic Design Co., acquired in 2021, and Resenex, acquired in 2024. It is Vance Street’s third acquisition in the medical and life sciences manufacturing sector in 2025, following Zenith Adhesive Component and MRPC.

“We are delighted to welcome Injectech to the VSC Medical Molding family,” said Jeff Kyle, CEO of VSC Medical Molding. “By combining VSC Medical Molding's precision molding and in-house tooling capabilities with Injectech's extensive component portfolio of custom and standard fluid management solutions, we are expanding our ability to deliver specialized solutions for our customers across critical medical, life science and bioprocessing applications.”

The company said the fluid management division will now include Injectech and Resenex, giving the platform a broader product range and expanded custom component capabilities. The segment will continue to focus on supplying the medical, life science and bioprocessing sectors.

“We are excited about the next chapter of growth and our partnership with VSC Medical Molding and Vance Street,” said Jeff Wicks, CEO of Injectech. “This combination will accelerate Injectech's growth and product innovation, further enhancing our ability to meet the evolving needs of our customers.”

“Injectech strengthens our VSC Medical Molding platform with deep expertise in precision fluid management and a culture of innovation,” added Steve Sandbo, partner at Vance Street Capital. “Together, we will continue building a leading precision molding and fluid management platform serving the medical device, life science and bioprocessing industries.”